Search
Bicara Therapeutics Inc
BCAXAdd to Watchlist
9.130USD
-0.600-6.17%
Close 10-30 16:00（ET）
604.13MMarket Cap
LossP/E TTM
BCAX Analyst Recommendation Trends
In the current month, BCAX has received 8 Buy Ratings, 0 Hold Ratings, and 1 Sell Ratings. BCAX average Analyst price target in the last month is 34.917.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
5
5
5
5
5
5
4
4
8
8
8
7
7
7
7
7
0
1
3
3
3
3
3
3
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
14
14
16
15
15
15
14
14
Financial Forecasting
Based on analysts' estimates, BCAX EPS is projected to reach -0.827 in FY2026Q3, following reported EPS of -0.816 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.67
-0.75
-0.83
-0.83
-0.87
Actual
-0.68
-0.93
-0.82
--
--
Surprise
-1.02%
-22.64%
+1.70%
--
--
FAQs
How have Bicara Therapeutics IncBCAX's recent earnings per share performed?
The market expectation was USD -0.82, while Bicara Therapeutics IncBCAX's earnings per share (EPS) for the previous quarter was USD -0.93. EPS for the next quarter is expected at USD -0.83.
What is the analyst rating for Bicara Therapeutics Inc?
Based on the ratings of Bicara Therapeutics Inc's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.